摘要
间充质干细胞因归巢性、低免疫原性、抗血管生成活性、抗炎性、旁分泌效应等特性,使其成为抗肿瘤研究的细胞疗法之一。紫杉醇作为抗肿瘤药已应用30余年,其广谱抗肿瘤特性是上述细胞疗法所不具备的,但仍存在周围神经病变、骨髓抑制、消化道反应等不良反应。近年许多研究聚焦于将细胞疗法与化疗两种疗法相结合,以达到更好的治疗效果,进而催生了以间充质干细胞作为载体呈递化疗药物的新型药物递送系统。该文综述了间充质干细胞运载紫杉醇的干细胞递送系统研究进展。
Mesenchymal stem cells have emerged as a promising cell therapy for anti-tumor research due to their homing properties,low immunogenicity,anti-angiogenic activity,anti-inflammatory properties,and paracrine effects.Paclitaxel has been clinically used for over thirty years in the treatment of various tumors such as ovarian cancer,lung cancer,and breast cancer.However,the broad-spectrum anti-tumor properties of paclitaxel are not possessed by the aforementioned cell therapies.Moreover,its adverse reactions,including peripheral neuropathy,bone marrow suppression,and gastrointestinal reactions,have long plagued cancer patients.In recent years,many studies have focused on combining cell therapy with chemotherapy to achieve better treatment outcomes,giving rise to a new drug delivery system that utilizes mesenchymal stem cells as carriers for delivering chemotherapeutic drugs.This review summarizes the research progress in MSC-based drug delivery systems for paclitaxel.
作者
裴奕浩
陈思遥
宿玉音
茅怡铭
李笨
PEI Yihao;CHEN Siyao;SU Yuyin;MAO Yiming;LI Ben(Department of Stomatology,Medical College of Jinzhou Medical University,Jinzhou,Liaoning 121000,China;Department of Medicine,Medical College of Jinzhou Medical University,Jinzhou,Liaoning 121000,China;Department of General Surgery,Shanghai Jiading District Anting Hospital,Shanghai 201805,China;Department of Thoracic Surgery,Suzhou Kowloon Hospital,Shanghai Jiao Tong University School of Medicine,Suzhou,Jingsu 215028,China)
出处
《军事医学》
CAS
CSCD
2024年第9期708-714,共7页
Military Medical Sciences
基金
国家级大学生创新创业训练项目(202313213001X)
辽宁省教育厅基本科研面上项目(JYTMS20230682)。
作者简介
裴奕浩,男,研究方向:基于干细胞的药物递送系统作用机制,Tel:18840102205,E-mail:yihaopei0413@outlook.com;通信作者:茅怡铭,Tel:13962146528,E-mail:253992240@qq.com;通信作者:李笨,Tel:15524436701,E-mail:15524436701@163.com。
